Advertisement

Topics

SANOFI Company Profile

10:19 EST 17th December 2018 | BioPortfolio

SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide:

  • DIABETES
  • CANCER
  • CARDIOVASCULAR DISEASES
  • INFECTIOUS DISEASES
  • ELEDERLY PATIENTS & AGING
  • OPHTHALMOLOGY
  • RARE DISEASES &
  • MULTIPLE SCLEROSIS

R&D PORTFOLIO

At the beginning of February 2013, SANOFI had 64 projects and vaccines under clinical development including 17 in phase 3 or submitted to healthcare authorities in the R&D portfolio of Sanofi.

Since the publication of the third quarter results, on October 25, 2012, Sanofi received the following regulatory decisions:

  • The approval of Zaltrap® (aflibercept) by the European Commission in metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.
  • The approval of Lyxumia® (lixisenatide) by the European Commission in type 2 diabetes and the submission to the FDA mid-December.
  • The FDA approval of Kynamro™ (mipomersen sodium, development partnership with Isis Pharmaceuticals) for the treatment of patients with Homozygous Familial Hypercholesterolemia.
  • The FDA accepted for review the supplemental biologics license application file seeking approval of Lemtrada™ (alemtuzumab, being developed in Multiple Sclerosis in collaboration with Bayer Healthcare) for the treatment of relapsing multiple sclerosis.
  • In addition, ENCORE, the second pivotal phase III trial of the investigational oral therapy, eliglustat, in Gaucher disease, met its primary efficacy endpoint of clinical stability compared to Cerezyme®.

Location

54, rue La Boétie
Paris
75008
France

Contact

Phone: +33 (0)1 53 77 40 00


News Articles [618 Associated News Articles listed on BioPortfolio]

wikifolio whispers p.m. zu Sanofi, voestalpine, AT&S, Nordex und Borussia Dortmund

Sanofi 0.03% JGross (FAIRMOEG): Verkauf Sanofi - Gewinnmitnahme (24.10. 11:47) >> mehr comments zu Sanofi: www.boerse-social.com/launch/aktie/sanofi voestalpine -7.56% TraderHarald (KGV1015): Voest...

Managertausch bei Bayer und Sanofi

Personaltausch bei den Pharmakonzernen Bayer und Sanofi : Der bisherige Sanofi-Manager Stefan Oelrich wird zum 1. November Chef von Bayers Pharmasparte, wie der Dax-Konzern aus Leverkusen am Donne...

WDH/Managertausch bei Bayer und Sanofi

Personaltausch bei den Pharmakonzernen Bayer und Sanofi : Der bisherige Sanofi-Manager Stefan Oelrich wird zum 1. November Chef von Bayers Pharmasparte, wie der Dax-Konzern aus Leverkusen am Donne...

Sanofi announce cull of 670 French jobs

French pharma giant Sanofi has said that it will cut 670 jobs in France over the next two years. The company currently employs 25,000 employees across France. In speaking with the 710,000 strong CGT U...

Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautio...

Deals this week: Sanofi, EBOS, Menarini Asia-Pacific Holdings

Sanofi has signed an agreement with Evotec to integrate its infectious disease unit into the latter’s business. Sanofi will pay...Read More... The post Deals this week: Sanofi, EBOS, Menarini Asia-P...

Corruption in Biopharma: Sanofi Only the Latest Company Accused of Bribery

Paris-based Sanofi settled corruption charges with the U.S. Securities and Exchange Commission (SEC) for more than $25 million. Sanofi is far from the first pharma company to be accused of bribery.

Deutsche Bank senkt Ziel für Sanofi auf 87 Euro - 'Buy'

Die Deutsche Bank hat das Kursziel für Sanofi von 88 auf 87 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Der Zusammenschluss von Sanofi und Aventis habe in den vergangenen zehn Jahren krä.....

Drugs and Medications [50 Associated Drugs and Medications listed on BioPortfolio]

Nilandron [sanofi-aventis U.S. LLC]

NILANDRON (nilutamide)Tablets

Allegra d 12 hour allergy and congestion [Rebel Distributors Corp]

Allegra-D 12 Hour Allergy and Congestion

Allegra d 12 hour allergy and congestion [Chattem, Inc.]

Allegra-D 12 Hour Allergy and Congestion

Hiprex(methenamine hippurate tablets usp) [sanofi-aventis U.S. LLC]

HIPREX(methenamine hippurate tablets USP)

Taxotere [sanofi-aventis U.S. LLC]

These highlights do not include all the information needed to use TAXOTERE safely and effectively. See full prescribing information for TAXOTERE.  TAXOTERE (docetaxel) Injection Concentrate, Intraven...

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Dupixent, a New Entrant In the Asthma Lists.

Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will join Nucala, (mepolizumab), Cinqair ...

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning.

CYD-TDV is the first licensed dengue vaccine for individuals 9-45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the...

Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.

The live-attenuated Japanese encephalitis chimeric virus vaccine JE-CV (IMOJEV®, Sanofi Pasteur) elicits a robust antibody response in children, which wanes over time. Clinical efficacy is based on a...

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Background No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the...

Low-Grade Inflammation Decreases Emotion Recognition - Evidence from the Vaccination Model of Inflammation.

The ability to adequately interpret the mental state of another person is key to complex human social interaction. Recent evidence suggests that this ability, considered a hallmark of 'theory of mind'...

Clinical Trials [71 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

The purpose of this study is to determine bioequivalence of amodiaquine suspension ( Pfizer) and the WHO approved reference product Flavoquine® tablet ( Sanofi Aventis).

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vac...

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on v...

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

This trial will evaluate the use of a tetravalent vaccine against dengue. Primary objectives: - To describe the immune response to dengue before and after each vaccination with ...

Companies [66 Associated Companies listed on BioPortfolio]

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

Sanofi Aventis Groupe

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SA...

Sanofi Pharmaceuticals Incorporated

Sanofi Pharmaceuticals are the U.S. subsidiary of Sanofi-Synthelabo, the global healthcare company. With annual sales in excess of $5.6 billion and 30,000 employees in more than 100 countries, Sanofi-...

Sanofi Pasteur MSD AG

Sanofi Pasteur MSD is the only European company dedicated exclusively to vaccines and was founded in 1994, as a joint venture between Sanofi Pasteur and Merck and Co. Inc.Sanofi Pasteur MSD develops v...

More Information about "SANOFI" on BioPortfolio

We have published hundreds of SANOFI news stories on BioPortfolio along with dozens of SANOFI Clinical Trials and PubMed Articles about SANOFI for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SANOFI Companies in our database. You can also find out about relevant SANOFI Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record